MELANIE KOUMENTAKOS: Open Payments
NPI 1295925956 · AGAWAM, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,931 in 216 payments from 24 companies in 2025. Trend: 2023 $5,570 · 2024 $5,021 · 2025 $4,931
Food & beverage: $4,846Education: $85
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 49 | $855 |
| UCB, Inc. | 22 | $535 |
| Arcutis Biotherapeutics, Inc. | 20 | $463 |
| Novartis Pharmaceuticals Corporation | 18 | $392 |
| Janssen Biotech, Inc. | 14 | $356 |
| E.R. Squibb & Sons, L.L.C. | 15 | $338 |
| GENZYME CORPORATION | 8 | $303 |
| Galderma Laboratories, L.P. | 15 | $275 |
| Lilly USA, LLC | 13 | $246 |
| Amgen Inc. | 6 | $198 |
Products named: Bimzelx, SKYRIZI, Zoryve, DUPIXENT, RINVOQ, TREMFYA, Sotyktu, COSENTYX.
Industry payments across MA — which companies pay providers there.
